ABIVAX Société Anonyme - AAVXF

ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. Its principal products include ABX 464 that is in Phase II clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS; ABX 203, a therapeutic vaccine candidate, which is in Phase IIb/III clinical trials for the treatment of chronic hepatitis B; and ABX 196, an immunostimulant/adjuvant candidate that has completed Phase I clinical trials for iNKT cell agonists. It also develops vaccines for typhoid, meningitis B and C, and leptospirosis. In addition, the company’s pre-clinical programs comprise ABX 202 and ABX 221 for the treatment of Dengue fever; ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and ABX 311 for the treatment of Chikungunya. ABIVAX Société Anonyme has strategic partnerships with Heber Biotec and Vacunas Finlay. The company was incorporated in 2013 and is headquartered in Paris, France.